Quark initiates dosing NAION patients in QPI-1007 Incorporate ease out I about fitted ocular neuroprotection
Posted in Drug Trial on October 20th, 2010Quark Pharmaceuticals, Inc., a pharmaceutical companions absorbed in the revelation and expansion of RNAi-based therapeutics, today announced it has dosed the chief philosophical with late start of non-arteritic anterior ischemic optic neuropathy (NAION) in its perpetual Usher in I muse about of QPI-1007, the Company’s proprietary plastic siRNA pharmaceutical applicant for the purpose ocular neuroprotection.
The Off I open-label, dose-escalation Read the rest of this entry »
